Top journals this week: Nature Medicine / Gastroenterology / Hepatology / Clin Gastro Hep
Selectivity
9.9%
10 in the issue of 101 screened
in the issue 10in depth 18held 11filtered out 62
90.1% of what published this week did not make the issue. That filter is the product. A further 18 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0Reinforces 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. These are the 10 cards in the issue; every one quotes the standard it was measured against, with its source and review date. Click a segment to filter the issue.
The signal map
Each dot is a paper: evidence strength across, how far it moves the standard up, area = the journal's impact factor, colour = subspecialty. The shaded zone is a fixed bar (prospective cohort or better, refining the standard or better), so a big dot outside it is work the field rated highly that is not changing practice. Click a dot to open its card.
The 10 in the issue this week, ranked by signal score. Each anchored to the relevant standard of care. All in full below; 18 more, read and scored the same way, in one line each at the foot of the issue.
the 3 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
Rank by
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Endoscopyrct · n=591 · Aug 16, 2026 · Endoscopy · IF 11.8
New therapysedationbariatric endoscopyendoscopy quality
Clinical takeawayUse the COMBO device during sedated endoscopy in obese patients (BMI ≥28) to substantially reduce hypoxia risk compared to standard nasal cannula. The device maintains airway patency and enables continuous capnography monitoring, providing an effective strategy for high-risk patients.
What it foundCOMBO device (oropharyngeal airway with capnography and oxygenation) reduced hypoxia (SpO2 75-90% for <60 seconds) from 21.50% to 6.38% (absolute difference -15.13%, 95% CI -20.59 to -9.66, p<0.001) and subclinical respiratory depression from 27.65% to 15.10% in obese patients (BMI ≥28) during sedated endoscopy, without increasing other adverse events.
ContextSedation-induced upper airway obstruction and hypoxia are recognized risks in obese patients undergoing endoscopy. Standard nasal cannulae provide supplemental oxygen but do not prevent airway collapse. This multicenter trial demonstrates an integrated airway management device is significantly more effective, refining risk-reduction strategy for this population.
…Assess ASA class, Mallampati, BMI, OSA risk and fasting status before every sedated procedure.…Involve an anesthesiology specialist for emergency endoscopy with increased aspiration risk, hemodynamic instability, OR significant comorbidities, and electively for ASA >=3, Mallampati >=3, severe OSA or anticipated difficult airway.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Scale pre-sedation assessment, regimen and monitoring to patient risk and procedure complexity. Assess ASA class, Mallampati, BMI, OSA risk and fasting status before every sedated procedure. Propofol AND midazolam-with-opiate are both strongly recommended; propofol as first line is conditioned on national legislation and staffing, not on demonstrated superiority. Consider remimazolam in the elderly and in cardiorespiratory comorbidity. Whoever administers sedation must be able to rescue a patient one level deeper than intended. Involve an anesthesiology specialist for emergency endoscopy with increased aspiration risk, hemodynamic instability, OR significant comorbidities, and electively for ASA >=3, Mallampati >=3, severe OSA or anticipated difficult airway. Individualize GLP-1 receptor agonist management rather than withholding blindly. Discharge against a scoring system with an accompanying adult and 24-hour restrictions.
Clinical takeawayConsider psyllium for IBS patients as a trial therapy. Clinical response (endpoint varies by trial) occurred in 52% vs 44% with placebo, but this did not translate to significant improvement in overall symptom severity scores (SMD −0.25), suggesting the benefit may reside in patient perception or non-severity endpoints rather than objective symptom reduction. Beta-galacto-oligosaccharides (B-GOS) improved overall symptom scores in limited trials (n=2) but did not demonstrate clinical response benefit. Subtype-specific benefits (diarrhea-predominant, constipation-predominant, mixed) are unknown. Clinicians should clarify with patients what outcome they are pursuing before recommending.
What it foundFiber increased clinical response rates to 52% vs 44% with placebo (RR 1.21 [95% CI 1.03-1.41]); psyllium showed greater benefit (RR 1.53 [95% CI 1.06-2.19]). Overall symptom severity scores did not improve significantly (SMD -0.25 [95% CI -0.67 to 0.17]).
ContextFiber is widely used and recommended for IBS, but this is the first recent evidence synthesis. The meta-analysis confirms benefit specifically for psyllium over other fiber types. However, the disconnect between improved 'clinical response' and unchanged symptom severity scores suggests the benefit may differ in nature from objective symptom reduction, refining the broad fiber recommendation to a more selective approach.
Emergingsuggested applicable standard· American Gastroenterological Association-American College of Gastroenterology (AGA-ACG), 'American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation' (Chang L, et al., Gastroenterology 2023;164(7):1086-1106), 2023ShowHide
Decision at stakewhether fiber supplementation (and specifically psyllium) is effective for constipation-related symptoms in IBS-C
…The guideline attaches several qualifiers that must not be dropped: (1) among the fiber supplements the panel evaluated, psyllium (3 trials), bran (1 trial), inulin (2 trials), methylcellulose (no trials found), only psyllium appears to be effective, with 'very limited and uncertain' data on bran and inulin and no evidence base at all for methylcellulose; (2) there is no clear evidence that soluble or insoluble fiber is more effective for constipation specifically; (3) on implementation, 'fiber supplements can be used as first-line therapy for CIC, particularly for individuals with low dietary fiber intake,' and 'dietary assessment is important to determine total fiber intake from diet and supplements'; (4) 'a trial of fiber supplement can be considered for mild constipation before PEG use or in combination with PEG'; (5) the total daily fiber target cited by the guideline is 20-30 g/day from diet plus supplement, derived from the Academy of Nutrition and Dietetics figure of 14 g per 1,000 kcal; (6) flatulence is a commonly observed side effect and adequate hydration should be encouraged.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
In adults with chronic idiopathic constipation, the AGA-ACG panel suggests the use of fiber supplementation over management without fiber supplementation. This is a CONDITIONAL recommendation based on LOW certainty of evidence. The guideline attaches several qualifiers that must not be dropped: (1) among the fiber supplements the panel evaluated, psyllium (3 trials), bran (1 trial), inulin (2 trials), methylcellulose (no trials found), only psyllium appears to be effective, with 'very limited and uncertain' data on bran and inulin and no evidence base at all for methylcellulose; (2) there is no clear evidence that soluble or insoluble fiber is more effective for constipation specifically; (3) on implementation, 'fiber supplements can be used as first-line therapy for CIC, particularly for individuals with low dietary fiber intake,' and 'dietary assessment is important to determine total fiber intake from diet and supplements'; (4) 'a trial of fiber supplement can be considered for mild constipation before PEG use or in combination with PEG'; (5) the total daily fiber target cited by the guideline is 20-30 g/day from diet plus supplement, derived from the Academy of Nutrition and Dietetics figure of 14 g per 1,000 kcal; (6) flatulence is a commonly observed side effect and adequate hydration should be encouraged. Fiber's placement within the guideline's own hierarchy is itself part of the recommendation: polyethylene glycol, bisacodyl, sodium picosulfate, linaclotide, plecanatide and prucalopride carry STRONG recommendations, whereas fiber, magnesium oxide, lactulose, senna and lubiprostone carry CONDITIONAL ones.
Clinical takeawaySWE demonstrated similar performance to VCTE for MASLD risk stratification. If SWE is available at your institution, this study supports its use as an alternative to VCTE. If your institution is implementing an elastography program and choosing between modalities, either is supported by this evidence; decide based on cost, operator expertise, and availability. Ongoing VCTE use does not require change.
What it foundSWE and VCTE showed similar 60-month risk prediction for liver-related events in MASLD (time-dependent AUROC: AGA 0.770 vs 0.775, EASL 0.804 vs 0.805; no significant difference between modalities).
ContextThis prospective cohort study validates SWE against hard clinical endpoints (liver-related events) in MASLD, showing similar risk stratification performance to VCTE and establishing SWE as a viable alternative modality.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
New evidenceCrohn's diseaseulcerative colitisbiologicsanti-TNF
Clinical takeawayIn UC patients with active luminal disease requiring biologic escalation, anti-TNF therapy after vedolizumab shows lower remission rates and durability than anti-TNF as first-line or anti-TNF-to-anti-TNF switching. Consider moving anti-TNF earlier in the biologic sequence for UC, or anti-TNF-to-anti-TNF sequencing rather than vedolizumab-then-anti-TNF. In CD patients with active luminal disease, clinical effectiveness remains similar despite higher discontinuation rates, making the sequencing implications less clear.
What it foundIn UC, anti-TNF therapy after vedolizumab (90% of cases) had significantly lower remission rates at short- and long-term follow-up (p < 0.001) and higher treatment discontinuation (HR 1.69 vs first-line, HR 1.91 vs anti-TNF-to-anti-TNF); in CD, anti-TNF after ustekinumab (62% of cases) showed higher discontinuation (HR 1.55 vs first-line) without significant differences in clinical effectiveness.
ContextCurrent IBD guidelines recommend individualizing biologic sequencing based on prior response, but evidence comparing efficacy after different prior mechanisms of action is limited. This registry study provides observational evidence that in UC, the prior biologic choice affects subsequent anti-TNF effectiveness, with vedolizumab being particularly associated with reduced anti-TNF durability and remission. The CD findings are less decisive.
Refinessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Crohn’s Disease in Adults' (Lichtenstein GR, Loftus EV, Afzali A, et al., Am J Gastroenterol 2025;120(6):1225-1264). DOI 10.14309/ajg.0000000000003465, PMID 40701562.ShowHide
Decision at stakewhether to use anti-TNF therapy after prior failure of a non-anti-TNF biologic (vedolizumab, ustekinumab, etc.)
…Ustekinumab (strong, moderate); risankizumab (strong, moderate), and risankizumab over ustekinumab in prior anti-TNF exposure (conditional, low); mirikizumab (strong, moderate); guselkumab IV-then-SC or all-SC (strong, moderate).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS, PERIANAL FISTULIZING, POST-OPERATIVE and 3 more.
Our full summary of this standardShowHide
DIAGNOSIS: Use fecal calprotectin (cutoff >50-100 μg/g) to differentiate inflammatory from noninflammatory disease OF THE COLON (strong, moderate). Ileocolonoscopy with biopsies for suspected CD; biopsy uninvolved mucosa to define histologic extent; small bowel imaging is part of the initial workup (key concepts, ungraded). CT enterography is comparable to MR enterography for small bowel detection; MRE should be used PREFERENTIALLY in patients younger than 35 years and where serial examinations are likely, because of radiation avoidance, MRE is not a blanket first choice. Intestinal ultrasound is a radiation-free ADJUNCT to diagnosis and to monitoring treatment response (key concept, ungraded, not a graded recommendation). Perform routine endoscopic CRC surveillance in Crohn's colitis (strong, moderate). MILD-TO-MODERATE / LOWER PROGRESSION RISK: Recommend AGAINST oral mesalamine for induction or maintenance (strong, moderate); sulfasalazine should be considered ONLY for symptomatic mild COLONIC CD (key concept). Controlled ileal-release budesonide 9 mg daily for induction of symptomatic remission in mildly-to-moderately active ileocecal CD (strong, moderate), but recommend AGAINST ileal-release budesonide for MAINTENANCE (strong, low). MODERATE-TO-SEVERE / HIGHER RISK: SUGGEST AGAINST requiring failure of conventional therapy before initiating advanced therapy (conditional, LOW, a permission to skip step-up, not a mandate to start advanced therapy upfront). Oral corticosteroids for short-term induction only (strong, low). Recommend AGAINST azathioprine 1.5-2.5 mg/kg/d and 6-mercaptopurine 0.75-1.5 mg/kg/d for INDUCTION (strong, moderate), but SUGGEST the same agents and doses for MAINTENANCE after corticosteroid-induced remission (conditional, low). Check TPMT before starting azathioprine/6-MP (strong, low); measure NUDT15 variants in patients of East Asian ancestry and TPMT variants in all patients prior to thiopurine initiation (strong, moderate). Methotrexate up to 25 mg weekly IM/SC for maintenance after corticosteroid induction (conditional, low). Anti-TNF agents (IV infliximab, SC adalimumab, SC certolizumab pegol) for induction and maintenance (strong, moderate). Recommend COMBINATION IV infliximab + thiopurine over either agent alone in patients naive to both (strong, moderate). Vedolizumab IV for induction and maintenance of symptomatic remission (strong, moderate). Ustekinumab (strong, moderate); risankizumab (strong, moderate), and risankizumab over ustekinumab in prior anti-TNF exposure (conditional, low); mirikizumab (strong, moderate); guselkumab IV-then-SC or all-SC (strong, moderate). Upadacitinib for induction and maintenance in patients PREVIOUSLY EXPOSED TO ANTI-TNF (strong, moderate), the ACG does not endorse it as a first-line biologic-naive option. SC infliximab and SC vedolizumab are maintenance options in responders to IV induction (strong, moderate). PERIANAL FISTULIZING: infliximab for induction (strong, moderate); adalimumab (conditional, low); antibiotics added to infliximab or adalimumab (conditional, very low); vedolizumab, ustekinumab, upadacitinib each (conditional, VERY LOW). Drain perianal abscesses and place setons before escalating advanced therapy (key concept). POST-OPERATIVE: endoscopic assessment at 6-12 months after surgically induced remission over no monitoring (conditional, moderate); in LOW post-op recurrence risk, continued observation rather than immediate medical therapy (conditional, very low); imidazole antibiotics (metronidazole) 1-2 g/d after small intestinal resection (conditional, low); in HIGH-risk CD, anti-TNF to prevent endoscopic recurrence (STRONG, moderate) and vedolizumab (CONDITIONAL, low), these two are not co-equal. SURGERY/ABSCESS: intra-abdominal abscess >2 cm should be treated with antibiotics plus a drainage procedure, and immunosuppression HELD until drainage is achieved (conditional, low). DISEASE MODIFIERS: counsel active smokers to quit; use NSAIDs with caution; assess stress, depression and anxiety as part of comprehensive care (key concepts).
Clinical takeawayGLP-1 RAs are not yet established for IBD disease modification. Consider offering them to obese IBD patients (particularly those with metabolic comorbidities including MASLD or cardiovascular disease) primarily for obesity and comorbidity management, with close monitoring for gastrointestinal tolerability, coordination with endoscopy plans, and assessment of lean muscle mass preservation. Pending results of ongoing randomized trials evaluating disease-modifying effects.
What it foundPreclinical studies show that GLP-1 receptor agonists reduce visceral adiposity and attenuate proinflammatory signaling; emerging human data suggest they are safe in patients with IBD and associated with lower hospitalization and surgical rates in those with obesity, although effects on disease activity remain unclear.
ContextObesity affects over half of IBD patients and is associated with increased disease activity, reduced treatment response, and higher surgical risk. GLP-1 RAs have transformed obesity management in the general population and confer cardiovascular benefits. This review synthesizes preclinical mechanisms and emerging clinical safety data to support further investigation of GLP-1 RAs in IBD management.
Emergingsuggested applicable standard· ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes)ShowHide
Decision at stakewhether to offer glucagon-like peptide-1 receptor agonists to overweight or obese patients with UC, particularly those with cardiometabolic comorbidities
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. Treat mild-moderate disease with 5-ASA by route and extent (suppository for proctitis, enema for left-sided, oral plus rectal for extensive); if 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by EFFICACY TIER, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab; intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab; lower: adalimumab. PREVIOUSLY TNF-EXPOSED, higher efficacy: tofacitinib, upadacitinib, ustekinumab; lower: adalimumab, vedolizumab, ozanimod, etrasimod - S1P modulators are weakest in exactly this group. Do not cycle within the anti-TNF class after primary non-response; switch mechanism. Apply treat-to-target (STRIDE-II) to endoscopic improvement (MES 0-1). Screen for acute severe UC by Truelove-Witts and admit for IV steroids. Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.
Clinical takeawayCounsel patients taking acetaminophen on the hepatotoxic risk and overdose potential, particularly those using over-the-counter analgesics. Screen for acetaminophen use when evaluating unexplained transaminitis or ALT/AST elevation >100 U/L, given acetaminophen-alone products now account for one-third to one-half of medication-related liver injury cases.
What it foundAcetaminophen-alone exposures increased 349-380% from 2000 to 2024 and now account for one-third to one-half of medication-related liver injury cases (defined by ALT/AST >100 U/L), while APAP-combination products declined 60-85%.
ContextAcetaminophen's role in drug-induced liver injury is well-known. This analysis documents a major epidemiologic shift: acetaminophen-alone products now dominate (33-45% of cases, up 349-380%) while combination products declined 60-85% following FDA restrictions in the early 2010s, indicating regulatory efforts to limit APAP in combination formulations have redirected risk to isolated products.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Towers EB … Farah R · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyrct · n=60 · Aug 12, 2026 · BMC Gastro · IF 2.5
Clinical takeawayDo not add NAC to lifestyle counseling for MASLD. Although NAC was safe and well-tolerated, it provided no additional benefit over lifestyle intervention alone for fibrosis, insulin resistance, oxidative stress, or steatosis indices. Lifestyle modification remains the evidence-based foundation.
What it foundHigh-dose NAC (2400 mg/day) for 12 weeks did not significantly reduce serum malondialdehyde, fasting insulin, HOMA-IR, or hepatic fibrosis compared to lifestyle intervention alone in 60 non-diabetic MASLD patients; the control group (lifestyle alone) showed greater liver steatosis score reduction (p=0.004).
ContextNAC has theoretical antioxidant and hepatoprotective effects and has been studied in NASH/MASLD, but this RCT provides clear evidence it does not improve the hallmark features of the disease (steatosis, fibrosis, insulin resistance). Confirms that lifestyle intervention alone is the evidence-based foundation of MASLD management.
Emergingsuggested applicable standard· AASLD 2023 Practice Guidance, updated by AASLD Practice Guidance October 2024 (resmetirom) and November 2025 (semaglutide)ShowHide
Decision at stakeWhether N-acetylcysteine supplementation provides clinical benefit for non-diabetic MASLD patients
Diagnose MASLD by hepatic steatosis on imaging (or biopsy) plus at least one cardiometabolic criterion and exclusion of competing etiologies (significant alcohol use, other liver disease), then risk-stratify fibrosis using a sequential non-invasive approach: FIB-4 first, followed by a second-line imaging-based test (VCTE, MRE, or ELF) for indeterminate/high-risk FIB-4, with liver biopsy reserved for discordant or unclear cases.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Diagnose MASLD by hepatic steatosis on imaging (or biopsy) plus at least one cardiometabolic criterion and exclusion of competing etiologies (significant alcohol use, other liver disease), then risk-stratify fibrosis using a sequential non-invasive approach: FIB-4 first, followed by a second-line imaging-based test (VCTE, MRE, or ELF) for indeterminate/high-risk FIB-4, with liver biopsy reserved for discordant or unclear cases. Lifestyle modification (≥7-10% weight loss, Mediterranean diet, exercise) remains the foundation for all patients. For adults with MASH and F2-F3 fibrosis identified by non-invasive tests (VCTE 8-15 kPa, MRE 3.1-4.4 kPa, or ELF 9.2-10.5) rather than biopsy, AASLD now gives dedicated, updated practice guidance on both FDA-approved pharmacotherapies: resmetirom (Oct 2024 update) and semaglutide 2.4mg/week subcutaneous (Nov 2025 update, following August 2025 accelerated FDA approval based on ESSENCE trial data: 62.9% vs 34.3% MASH resolution without fibrosis worsening; 36.8% vs 22.4% ≥1-stage fibrosis improvement). Pioglitazone or vitamin E remain options per the 2023 base guidance. Manage cardiometabolic risk with statins for ASCVD reduction plus glycemic and blood-pressure control; for semaglutide specifically, routine hepatic panels are recommended only as clinically indicated (no discontinuations for LFT elevation in ESSENCE), with monitoring for GI adverse effects and rare risks (AKI, gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, lean mass loss). HCC surveillance with ultrasound and AFP every 6 months remains indicated only if cirrhosis is present.
New evidencecomputer-aided detectioncolonoscopyadenomaendoscopy quality
Clinical takeawayConsider adopting computer-aided detection systems in routine colonoscopy as an adjunctive tool. CADe remains independently associated with improved adenoma detection (aOR 1.31, 95% CI 1.11-1.55, p=0.002) after adjustment for endoscopist variation, confirming incremental benefit beyond endoscopy technique alone.
What it foundComputer-aided detection improved adenoma detection rate from 30.7% to 34.4% (aOR 1.31, 95%CI 1.11-1.55, p=0.002) and adenoma+clinically significant serrated polyp detection from 35.8% to 40.3% in a pragmatic real-world study of 2973 colonoscopies with within-endoscopist comparison.
ContextRandomised trials had shown CADe improves adenoma detection, but real-world translation remained uncertain with inconsistent results across observational studies. This pragmatic multicentre study confirms CADe provides independent benefit (aOR 1.31 after accounting for endoscopist factors), though the effect attenuates with endoscopist adjustment, revealing endoscopist skill as a substantial driver of detection rate.
Refinessuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017ShowHide
Decision at stakewhether to incorporate computer-aided detection technology during colonoscopy screening
Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.
Bernardes C … Pimentel-Nunes P · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Endoscopyretrospective · n=3,227,805 · Aug 15, 2026 · Dig Dis Sci · IF 2.5
What it foundUpper GI bleeding occurred in 83% of GI complications during PCI hospitalizations with 12.4% in-hospital mortality versus 6.1% for lower GI bleeding (adjusted odds ratio 1.74, 95% CI 1.36-2.23), while UGIB incidence rose from 0.90% to 1.13% over 2016-2022.
ContextNational inpatient sample data (2016-2022) document the epidemiology of gastrointestinal bleeding during percutaneous coronary intervention hospitalizations, with distinct incidence, clinical features, and in-hospital outcomes for upper versus lower bleeding events.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Alnounou A … Sengupta N · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗Permalink
Motility· 1
Motilityrct · n=143 · Aug 18, 2026 · J Gastro Hep · IF 3.5
Clinical takeawayIn IBS-D patients responding to rifaximin, consolidation with 4 weeks of Medilac-S (Bacillus subtilis and Enterococcus faecium) may be considered to reduce relapse risk. Clinicians should note this contradicts current ACG recommendations against probiotics in IBS (conditional, very low evidence against).
What it foundIn IBS-D patients responding to rifaximin, 4-week Medilac-S consolidation therapy reduced relapse from 58% to 40% (p=0.0378) and improved bowel frequency (1.73 vs 2.53 stools/day, p<0.001) and stool consistency (BSFS 4.38 vs 5.15, p<0.001).
ContextRifaximin achieves good initial remission but relapse remains common. This open-label multicenter RCT tested post-rifaximin probiotic consolidation in a specific population (rifaximin-responders). While the 18-point relapse reduction is clinically meaningful, the open-label design and borderline significance (p=0.0378) mean this single trial does not overturn guideline guidance; should involve shared decision-making and explicit discussion that this is an off-guideline approach.
Refinessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021ShowHide
Decision at stakewhether to recommend probiotics in IBS-D management
…IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes IBS-C.
Our full summary of this standardShowHide
Diagnosis: use a positive diagnostic strategy based on Rome IV criteria rather than a strategy of exclusion (strong for cost-effectiveness, high quality; consensus for time-to-therapy), and categorize by IBS subtype (consensus). In patients with IBS and diarrhea symptoms: check celiac serology (strong, moderate) and, in those WITHOUT alarm features, fecal calprotectin (or fecal lactoferrin) plus CRP to rule out IBD (strong; moderate quality for CRP/calprotectin, very low for lactoferrin). Recommend AGAINST routine stool testing for enteric pathogens (conditional, low) and AGAINST routine colonoscopy in patients younger than 45 without warning signs (conditional, low). Anorectal physiology testing only when symptoms suggest a pelvic floor disorder and/or for refractory constipation not responding to standard medical therapy (consensus). Treatment, all subtypes: soluble, not insoluble, fiber (strong, moderate); a LIMITED trial of a low-FODMAP diet (conditional, very low); gut-directed psychotherapies for global symptoms (conditional, very low); TCAs for global symptoms (strong, moderate); peppermint suggested (conditional, low); antispasmodics for abdominal pain (conditional, low); AGAINST probiotics (conditional, very low), AGAINST fecal transplant (strong, very low). IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).
Zhong J … Wang L · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Everything else this week18 that cleared the barShowHide
Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.
Also screened this week25 papers read, not selectedShowHide
These cleared the journal filter and were read, but were not
selected this week. A score means the paper was weighed: below 35 it fell
short of the bar; at 35 or above, a check after scoring set it aside. A blank
means it was set aside before scoring. Listed for anyone going deeper; no
takeaway attached, because none was written.
How we choose →